Rafferty Asset Management’s Definium Therapeutics DFTX Stock Holding History

Rafferty Asset Management’s Portfolio DFTX Stock Details DFTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$402K	Buy	+8,548	New	+$211K	﹤0.01%	947
2026 Q1	–	Sell	-18,885	Closed	-$253K	–	1115
2025 Q4	$253K	Buy	18,885 +6,210	+49%	+$76.8K	﹤0.01%	1030
2025 Q3	$149K	Buy	+12,675	New	+$118K	﹤0.01%	1086
2025 Q2	–	Sell	-13,773	Closed	-$80.6K	–	1095
2025 Q1	$80.6K	Buy	+13,773	New	+$98.6K	﹤0.01%	1051
2024 Q4	–	Sell	-18,658	Closed	-$106K	–	1163
2024 Q3	$106K	Buy	18,658 +1,359	+8%	+$9.45K	﹤0.01%	1127
2024 Q2	$125K	Buy	+17,299	New	+$151K	﹤0.01%	1156

Other funds holding DFTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Rafferty Asset Management's DFTX Position: Q2 2026 in Review

Rafferty Asset Management opened a new position in Definium Therapeutics (DFTX) in Q2 2026: 8,548 shares worth $402K. The stake represents ﹤0.01% of the portfolio and ranks #947 among its holdings. This is a return to the name: Rafferty Asset Management previously reported a position in DFTX as recently as Q4 2025.

Rafferty Asset Management first reported a position in DFTX in Q2 2024 and has held it in 6 quarters since. 362 funds tracked by Wall St. Rank hold DFTX as of Q2 2026.

Rafferty Asset Management held 8,548 shares of Definium Therapeutics worth $402K as of Q2 2026.
Definium Therapeutics was a new Rafferty Asset Management position in Q2 2026.
Definium Therapeutics made up ﹤0.01% of Rafferty Asset Management's portfolio in Q2 2026, its #947 holding.
Rafferty Asset Management first reported a position in Definium Therapeutics in Q2 2024 and has held it in 6 quarters since.
362 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2026.

Based on Rafferty Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.